FOLLOW US

Endocrine Research Updates

For Medical Professionals

A 7-question survey helps clinicians tailor treatment for hypothyroidism.
In patients with Hashimoto’s thyroiditis, adjusting for levothyroxine dose and formulation should be informed by EMPATHY trial findings to attain TSH range and achieve optimal patient compliance.
Employing a 7-question survey may improve individualized dosing and bioavailability of levothyroxine for hypothyroidism to optimize therapeutic efficacy.
Applying the 2019 Obesity Guide will achieve better weight controls for patients
Despite our failed efforts historically, the myriad tools from pharmacotherapy to devices and gastric procedures now available should prompt renewed focus on individualizing care to improve morbidity and mortality, aided by the 2019 Obesity Algorithm.
Obesity is a disease requiring clinical attention that should be informed by the 2019 Obesity Algorithm identifying devices, procedures, and approaches useful in creating individualized weight loss plans.
The Spatz adjustable intragastric balloon helps break through a weight plateau.
Obesity remains a fundamental clinical challenge to be aided by a range of new weight loss devices that promise to meet the varying needs of individual patients as spotlighted at Digestive Disease Week.
3 innovative approaches aimed to improve weight loss success were unveiled at DDW 2019, including an endoscopic gastric sleeve, a fecal matter capsule, and a gastric balloon.
ACR/ATA criteria offers guidance on when thyroid imaging should be used.
ACR/ATA recommendations clarify the occasions in which thyroid imaging is advisable and when it is not to optimize patient management.
Criteria have been developed to direct thyroid imaging to only those conditions that warrant this technology to lessen time and unnecessary costs.
An IGF-1 monoclonal antibody finally provides effective for Graves' eye disease.
Effective therapeutic options for Graves’ ophthalmology have been elusive, which makes the favorable outcomes of an investigation monoclonal antibody that acts on the IGF-IR pathway great news for patients with hyperthyroidism.
Investigational Biologic offers the first effective treatment to improve symptoms of Thyroid Eye Disease in 800,000 most of whom have hyperthyroidism.
FDA approves noninvasive, removable gastric devices for weight loss.
Novel adjunctive endoscopic and oral non-invasive methods of weight loss are gaining interest and attention but will need reimbursement in order to assure full access once on the market.
FDA clears two novel weight loss devices and oral products show strong evidence of substantial effectiveness, with 10% weight loss possible.
Individuals treated for thyroid cancer gain no benefit from TSH therapy.
Aggressive TSH suppression offers little to no benefit in patients with differentiated thyroid cancer patients at low risk of recurrence and death based on a comprehensive review of the literature.
TSH suppression therapy is deemed unnecessary for most patients with thyroid cancer at low risk for recurrence.
Loss of 55 of baseline body weight can be maintained by taking metformin.
Latest findings from the Diabetes Prevention Program Outcomes trial reinforced benefit of taking metformin to maintain long-term weight loss at least among those with prediabetes who achieved modest weight loss during year one.
Taking metformin may help thwart diabetes in individuals who lose at least 5% keeping lost weight off for at least 15 years
The onset of a new form of autoimmune, insulin-dependent diabetes are among the possible adverse events requiring vigilance to detect and manage as more patients receive monoclonal antibody therapy for cancer.
Rising use of checkpoint inhibitors for cancer treatment may lead to autoimmune type 1 diabetes as well as thyroid disorders and pituitary issues.
Achieving a 30% decline in urinary albumin means improvements in kidney disease
A decrease in urinary albumin appears effective as a surrogate biomarker for chronic kidney disease, based on results of meta-analysi, with; implications for research and clinical practice
Robust review of studies confirms a role for albuminuria as a valid marker for end-stage renal disease, including in patients with diabetes and heart disease.
People with type 2 diabetes can safely take a proton pump inhibitor long-term..
Given the influences of the gut microbiome, researchers explored the potential benefits and adverse effects of long-term use of PPIs on the pancreas and liver in people with type 2 diabetes.
Researchers explored concerns regarding possible adverse effects of long-term use of proton pump inhibitors in people with type 2 diabetes.
Treating hypogonadism with Testosterone can prevent progression of diabetes.
Testosterone replacement halted the progression to diabetes in 90% of men who had hypogonadism, achieving improvement risk factor measures including body weight and lipids, in men who had a diagnosis of prediabetes prior to treatment.
Diabetes is common in men with hypogonadism. If diagnosed and treated with testosterone, diabetes and its common complications can be prevented.
New diabetes devices meet patient need for more reliable device design.
A series of recent Food and Drug Administration actions reflect a desire to meet consumer demands for ease of diabetes product use across multiple platforms, and more..
FDA clears diabetes devices that fulfill patient desires for fully automate interoperability between glucose management products to work in real life settings.
Female pattern hair loss has a markedly different pattern than occurs in men.
Female pattern hair loss is a bonafide quality of life issue that deserves clinical action based on recently introduced evidence based recommendations that may or may not arise from androgen excess.
Most pituitary tumors are benign but the rare cancerous ones requires vigilance.
Review study raised questions about identification and treatment of rare pituitary adenomas. For now, individualized management should remain the standard of care.
Obesity is often difficult to overcome due to feelings of shame.
Given the continuing rise in obesity and associated chronic conditions, having the tools to help patients will matter little if there is no patient-provider acknowledgement of the problem. Retool your practice for better weight control outcomes in your patients.
Common obstacles to weight loss include the lack of properly sized equipment in doctor's offices and a sense of shame. By showing empathy and offering personalized recommendations, doctors can effect change.
For patients receiving transgender hormone therapy, monitor for CVD.
For individuals receiving transgender hormone therapy, the focus of clinical care should be on reducing known cardiovascular risk factors to support optimal patient outcomes.
Patients receiving transgender hormone therapy, especially transgender women faced an increased risk for CVD events, which can be managed with usual care.
GMI becomes key blood glucose value for patients with CGMs.
Validation of the Glucose Management Indicator (GMI) as an acceptable replacement for “estimated HbA1c” in patients using continuous glucose monitoring grows with the endorsement of the FDA.
Know the new diabetes devices becoming available and for which patients.
Given the avalanche of app approvals, product updates, and study findings, here’s what to watch for as the future of clinical diabetes management unfolds.
Digital food logs improve the experience and keep people going to lose weight.
Encouraging your patients to keep track of their food intake should be encouraged to promote suistainable weight loss given the easy access to online tools and smartphone apps that cut down on time.
Using a digital food tracker or mobile food journaling app for as little as 15 minutes daily promises meaningful weight loss for those who stick with it.
close X
SHOW MAIN MENU
SHOW SUB MENU